A QSAR study on 2-(4-methylpiperazin-1-yl)quinoxalines as human histamine H4 receptor ligands

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 3, 2011, Pages 412-421

  Sharma, Brij K ^a   Pilania, Pradeep ^a   Singh, Prithvi ^a   Prabhakar, Yenamandra S ^b  

^a SK Government College   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

2 (4 methylpiperazin 1 yl)quinoxalines; combinatorial protocol in multiple linear regression (CP MLR); histamine H4 receptor (H4R); partial least square (PLS) analysis; QSAR

Indexed keywords

2 (4 METHYLPIPERAZIN 1 YL)QUINOXALINE DERIVATIVE; HISTAMINE H4 RECEPTOR; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

HUMANS; LIGANDS; PIPERAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOXALINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE;

EID: 79955558555     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.519702     Document Type: Article

References (33)

1. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990; 42:45-83. (Pubitemid 20209593)
2. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972;236:385-390.
3. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJP. Histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005;23/24:1613-1627. (Pubitemid 41817610)
4. Liu C, Ma X-J, Jiang X, Wilson SJ, Hofstra CL, Blevitt K, Li X, Chai W, Carruthers N, Lovenberg TW. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 2001;59:420-426. (Pubitemid 32179918)
5. Morse KL, Behan J, Laz TM, West RE Jr, Greenfender SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Green J, Bayne M, Monsma FJ Jr. Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 2001;296:1058-1066. (Pubitemid 32187382)
6. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001;59:427-433. (Pubitemid 32179919)
7. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000;275:36781-36786. (Pubitemid 32002087)
8. Zhu Y, Michalovich D, Wu H-L, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, Herrity NC, Vawter L, Sarau HM, Ames RS, Davenport CM, Hieble JP, Wilson S, Bergsma DJ, Fitzgerald LR. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 2001;59:434-444.
9. de Esch IJP, Thurmond RLJA, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005;26:462-469. (Pubitemid 41207878)
10. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB. Histamine H4 and H2 receptors control histamine induced interleukin-16 release from human CD8+ T cells. J Pharmacol Exp Ther 2002;303:300-307.
11. Varga C, Horvath K, Berko A, Thurmond RL, Dunford PJ, Whittle BJ. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 2005;522:130-138. (Pubitemid 41456659)
12. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004;309:404-413. (Pubitemid 38393154)
13. Ikawa Y, Suzuki M, Shiono S, Ohki E, Moriya H, Negishi E, Ueno K. Histamine H4 receptor expression in human synovial cells obtained from patients suffering from rheumatoid arthritis. Biol Pharm Bull 2005;10:2016-2018. (Pubitemid 41437104)
14. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br J Pharmacol 2004;142:374-380. (Pubitemid 38750189)
15. Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, Bani D, Messerini L, Fabbroni V, Perigli G, Capaccioli S, Masini E. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005;19(Pt 1):6807-6815. (Pubitemid 41428735)
16. Smits RA, Lim HD, Hanzer A, Zuiderveld OP, Guaita E, Adami M, Coruzzi G, Leurs R, de Esch IJP. Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem 2008;51:2457-2467. (Pubitemid 351628507)
17. Kiss R, Kiss B, Könczöl Á, Szalai F, Jelinek I, László V, Noszál B, Falus A, Keserû GM. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem 2008;51:3145-3153. (Pubitemid 351821875)
18. Todeschini R, Consonni V. Dragon software (version 1.11-2001). Milano, Italy.
19. Chemdraw Ultra 6.0 and Chem3D Ultra. Cambridge Soft Corporation, Cambridge, USA.
20. Smits RA, Lim HD, Stegink B, Bakker RA, de Esch IJP, Leurs R. Characterization of the histamine H4 receptor binding site: Part I. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem 2006;49:4512-4516. (Pubitemid 44162677)
21. Prabhakar YS. A combinatorial approach to the variable selection in multiple linear regression: analysis of Selwood et al. data set-a case study. QSAR Comb Sci 2003;22:583-595. (Pubitemid 37010625)
22. Sharma BK, Pilania P, Singh P. Modeling of cyclooxygnase-2 and 5-lipooxygenase inhibitory activity of apoptosis inducing agents potentially useful in prostate cancer chemotherapy: the derivatives of diarylpyrazole. J Enz Inhib Med Chem 2009;24:607-615.
23. Sharma S, Sharma BK, Pilania P, Singh P, Prabhakar YS. Modeling of the growth hormone secretagogue receptor antagonistic activity using chemometric tools. J Enz Inhib Med Chem 2009;24:1024-1033.
24. Sharma BK, Pilania P, Singh P, Prabhakar YS. Combinatorial protocol in multiple linear regression/partial least-squares directed rationale for the caspase-3 inhibition activity of isoquinoline- 1,3,4-trione derivatives. SAR QSAR Environ Res 2010;21:169-185.
25. Sharma BK, Pilania P, Sarbhai K, Singh P, Prabhakar YS. Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives. Mol Divers 2010;14:371-384.
26. Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978;20:397-405.
27. Kettaneh N, Berglund A, Wold S. PCA and PLS with very large data sets. Comput Stat Data Anal 2005;48:69-85.
28. Stahle L, Wold S. Multivariate data analysis and experimental design. In: Ellis GP, West WB. Eds., Biomedical research. Progress in medicinal chemistry. Elsevier Science Publishers, BV, Amsterdam. 1988;25:291-338.
29. Topliss JG, Edwards RP. Chance factors in studies of quantitative structure-activity relationships. J Med Chem 1979;22:1238-1244. (Pubitemid 10237430)
30. Katritzky AR, Dobchev DA, Slavov S, Karelson M. Legitimate utilization of large descriptor pools for QSAR/QSPR models. J Chem Inf Model 2008;48:2207-2213.
31. So S-S, Karplus M. Three-dimensional quantitative structure- activity relationship from molecular similarity matrices and genetic neural networks. 1. Method and validation. J Med Chem 1997;40:4347-4359. (Pubitemid 28042314)
32. Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB. CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb Sci 2004;23:234-244. (Pubitemid 39490415)
33. Gramatica P. Principles of QSAR models validation: internal and external. QSAR Comb Sci 2007;26:694-701. (Pubitemid 46932857)